Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 36-month results from first-in-human study with shape-changing IOL
➤ New data for recently approved EDOF IOL
➤ Company completes first-in-human robotic cataract surgery
➤ Phase 2 study approved for secondary IOL intended for low-vision patients
➤ Investigational device measures real-time intraoperative aqueous outflow
➤ FDA expands dosing on label for faricimab
➤ Company news
➤ ASCRS news and events
➤ Keep up with ASCRS Annual Meeting coverage with EyeWorld Onsite
➤ Positive topline results from Phase 3 trial for TED drug with new delivery method
➤ FDA expands dosing interval for wet AMD, DME treatment
➤ IDE granted to noninvasive bioelectric stimulation therapy for dry AMD
➤ First patients dosed in Phase 3 corneal cell therapy
➤ TED investigational treatment fails to meet primary endpoint
➤ OTC eye drop recall after FDA enforcement report cites sterility concerns
➤ ASCRS news and events
➤ Positive topline data from Phase 3 study for thyroid eye disease treatment
➤ Controlled U.S. release of outflow restoration platform for glaucoma
➤ New platform established to help bring supportive evidence to interventional glaucoma
➤ Head-to-head Phase 1b study supports investigational anti-VEGF
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ FDA issues another response letter for dry eye NDA
➤ FDA denies approval for LHON NDA
➤ Commercial launch of epithelium-on crosslinking in the U.S.
➤ Company news
➤ ASCRS news and events
➤ First patients dosed in Phase 3 program evaluating sustained drug delivery for DME
➤ FDA accepts supplemental NDA for presbyopia treatment
➤ FDA grants IND to ocular inflammation, pain treatment for potential expanded indication
➤ Enrollment complete in Phase 3 trial evaluating retinitis pigmentosa therapy
➤ ASCRS news and events
➤ Enrollment complete in Phase 3 trial for wet AMD
➤ Dosing complete in Phase 1/2 trial for retinitis pigmentosa treatment
➤ First patient dosed in gene therapy study for optic nerve disorder
➤ Company news
➤ New drop for temporary presbyopia relief approved
➤ First-in-human results for accommodating IOL
➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy
➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response
➤ First patient receives investigational surgical system for glaucoma
➤ Clinical program for RP gene therapy begins
➤ FDA approves IND for steroid-free, topical anti-inflammatory
➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ Enrollment complete in first-in-human trial evaluating treatment for patients with Usher syndrome
➤ First patients randomized in drug-eluting IOL trial
➤ Preliminary data from Phase 2 gene modifier study for geographic atrophy
➤ ASCRS news and events
➤ Study: ‘revolutionary,’ ‘world-first’ treatment for vision-threatening condition restores sight ➤ IDE granted to tissue-based presbyopia solution ➤ Fast Track designation granted for geographic atrophy treatment ➤ Phase 1 results for Stargardt gene therapy ➤ Topline Phase 1b results from study comparing a next-gen treatment to faricimab ➤ Enrolled patients complete dosing in part of trial evaluating X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
